The Company is a Korea-based company mainly engaged in the medical business based on radioactive fusion technology. The Company is engaged in the manufacture and sale of radiopharmaceuticals used in the diagnosis of oncology, prostate, liver, lung and brain cancers as well as others. The Company is also engaged in the manufacture and sale of pheochromocytoma treatment, liver cancer treatment and other products. The Company was founded on December 18, 2012 and its shares are listed on KOREA NEW EXCHANGE(KONEX) on December 23, 2022.
Headquarters
567, Baekje-Daero, Deokjin-Gu
Jeonju; Jeollabuk;
Contact Details: Purchase the Kaibiotech Co., Ltd. report to view the information.
Website: http://www.kaibiotech.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service